Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166256

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Disclosure of effect of changes in foreign exchange rates [text block]
4
Disclosure of information when currency is not exchangeable into another currency [text block]
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]
Disclosure of summarised financial information about foreign operation [text block]
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets
11,063,000 EUR
9,485,000 EUR
Current assets
50,801,000 EUR
53,959,000 EUR
Non-current liabilities
1,047,000 EUR
409,000 EUR
Current liabilities
5,772,000 EUR
14,978,000 EUR
Revenue
2,951,000 EUR
3,096,000 EUR
Profit (loss)
10,770,000 EUR
11,579,000 EUR
Other comprehensive income
- EUR
- EUR
Comprehensive income
10,770,000 EUR
10,770,000 EUR
- EUR
- EUR
- EUR
- EUR
11,579,000 EUR
11,579,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.